Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MWN109 in healthy volunteers for obesity treatment
NCT06938269Phase 1Recruiting
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd.
- Start
- Jun 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MWN109 in obesity (8 arms), sponsored by Shanghai Minwei Biotechnology Co., Ltd. Primary endpoints: Treatment Emergent Adverse Events, Change in Laboratory Parameters and 4 more. Started Jun 2025; status: recruiting.
02
Drugs
MWN109
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06938269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06938269.